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Summary: A very sensitive, optimized bioluminescent assay for creatine kinase and creatine kinase MB activi-
ties is tested. We evaluated reagent blanks, sensitivity, precision and compared the results with those of the
spectrophotometric immunoinhibition test. The main advantage of the new method is a detection limit of less
than l U/l which, together with a high precision (s = 0.1 at detection limit), allows determinations of the
creatine kinase MB activity even in normal sera in about 20 minutes. A disadvantage of the manual procedure
is that it may be necessary to include up to five pipetting Steps.
Evaluierung der optimierten Biolwnineszenzmethode zur Bestimmung von Gesamtkreatinkinase- und
Kreatinkinase M B-Aktivitäten
Zusammenfassung: Wir berichten über unsere Erfahrung mit der sehr empfindlichen Biolumineszenzme-
thode zur Bestimmung von Kreatinkinase- und Kreatinkinase MB-Aktivitäten. Insbesondere untersuchten
wir Reagentienleerwerte, Sensitivität und Präzision. Darüberhinaus verglichen wir die Ergebnisse dieser
neuen Methode mit denen des spektrophotometrischen Immuninhibitionstestes. Der Hauptvorteil der neuen
Methode ist in ihrer hohen Empfindlichkeit zu sehen, die Aktivitätsbestimmungen der Kreatinkinase MB
selbst in Normalseren innerhalb von 20 Minuten erlaubt. Die Nachweisgrenze für die Kreatinkinase-Aktivität
liegt unter l U/l bei einer Standardabweichung von 0,1 U/l. Nachteilig ist die manuelle Durchführung mit bis
zu fünf verschiedenen Pipettierschritten.
Introduction
The determination of the activities of creatine ki-
nase2) and its isoenzyme creatine kinase MB is wide-
ly used for the detection of muscle cell damage. The
activity of the MB isoenzyme is especially valuable in
the diagnosis of myocardial infarction (1).
') Part of the M.D.-thesis of K.-H. Willig.
2) Nonstandard abbreviations used: CX = Crealine kinase, ATP:
Creatine-N-phosphotransferase, EC 2.7.3.2.
CK-MM, CK-MB, CK-BB = skeletal muscle, heart and brain
type creatine kinase isoenzymes
AK = Adenylate kinase, ATP:AMP-phosphotransferase, EC
2.7.4.3
Firefly luciferase, EC 1.2.3.-.
s = Standard dcviation.
The optimized bioluminescent assay for creatine ki-
nase MB activity is based on the backward reaction
using creatine phosphate and ADP äs Substrates. Its
sensitivity is based on the light-emitting firefly luci-
ferin-luciferase reaction (2) instead of the usual
spectrophotometric assay of NADPH. The adeny-
late kinase problem is circumvented by incorporat-
ing inhibitors of adenylate kinase activity (AMP, di-
adenosine pentaphosphate) into the reaction mix-
ture and by running a blank in which the Substrate
creatine phosphate is omitted. The specificity of the
assay for creatine kinase MB is based on the specific
and total Inhibition of the creatine kinase M subunits
by goat anti creatine kinase M antibodies (3). After
Inhibition of all M subunits the residual creatine ki-
J. Clin. Chem. Clin. Biochem. / Vol. 21„ 1983 / No. 9
584 Willig, Siein and Bohnen Evaluation of the optimizcd biolumincsccnt assay for crcatine kinase
nasc activity in patients' sera is the rcsult of either
crcatine kinase MB, creatine kinase BB or macro
creatine kinases. In patients with suspected myocar-
dial infarction this residual creatine kinase activity
after immunoinhibition can be regarded s creatine
kinase MB activity, because in this group of patients
the occurrence of creatine kinase BB (4, 5) or macro
creatine kinases (6) is a rare event.
In the following we describe the results of our eva-
luation of this bioluminescent assay of creatine ki-
nase with fresh and frozen sera. As a reference
method we used a mechanized spectrophotometric
immunoinhibition assay.
Materials and Methods
P r i n c i p l e
The principle of the bioluminescent assay for the detcrmination of
creatine kinase MB is very similar to the spectrophotometric as-
say. However, apart from the indicator reaction there are other
important differences in the concentrations of some reagents:
creatine phosphate,NADP concentrations, and the volume fraction
of the sample differ widely in both assays. For details see table 1.
Tab. 1. Reactants and products of the bioluminescent assay of
creatine kinase and final concentrations of the reagents
{*·· t·)· crcatine kinase
Phosphocreatine + ADP v > creatine + ATP
ATP + luciferin + O2 'UC' *"*% AMP + pyrophosphate +























































The choice of the imidazole buffer is in accordance with the re-
commendations of the German and Scandinavian Societies for
Clinical Chemistry (1) for the optimal reaction conditions of crea-
tine kinase. However, the pH Optimum of luciferase is in the r nge
of pH 7.75 (2), so an internal calibration with known amounts of
ATP is included in the reaction sequence to compensate for this
different pH Optimum.
Sera s tud ied
The samples were obtained from patients of our hospital. Sera
were assayed either directly or stored at 4 °C for up to 48 h or at
-20 °C with 20 mmol/1 of 2-mercaptoethanol s additive.
B i o l u m i n e s c e n t assay
Bioluminescence caused by creatine kinase activity was monitorcd
with a Luminomcter 1250 connected with a potentiornetric re-
cordcr 2210, a Teletype printer and a Databox-Luminescencc-
Analyzer 1231-001 (LKB-Wallac, Turku, Finland), Temperature
of the cuvette (disposable polystyrene tubes, 12 x 55 mm, Nr.
55484, W. Sarstedt, N mbrecht, F.R.G.) and the preincubation
bath was held at 25 °C with a circulating water bath (Haake,
Karlsruhe, F.R.G. ). Determinations of total activities and creatine
kinase MB activities were performed s manual procedures with
reagents from LKB-Wallac (No. 1243-101, lots: 13001, 19009,
1 90 1 3, 1 9014). The assays were run with intetnal ATP calibration
Standards according to the manufaeturer's histructions (LKB No.
13900031) (fig. I) with the following exceptions:
l . The rate of increase of light emission (slope, S) was measured
with the databox for exactly 20 seconds after a· 10 seconds lag
phase, following the addition of ADP Substrate and creatine phos-
phate Substrate ($CK, SAX or SMB+AK (mV/min) values).
2. After addition of the internal ATP Standard^ light emission was
monitored for exactly 10 seconds with the databox (ICK, IAK or
I M B + A K (mV) values).
3. Internal calibration with ATP Standard was performed in every
sample with enzyme activity below 50 U/I. All these ATP Stand-
ard values (loc, IAK, IMB+AK) were reported and an average
Standard value Ϊ was calculated daily.
4. In samples with enzyme activities exceeding 50 U/l the internal
calibration and calculation with the databox resulted in imprecise
values. Therefore, we had to use the average ATP Standard values
and to calculate the enzyme activities with a separate calc lator:
CK-MB activity = (;MptAK - ̂
IMB+AK IAK
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Fig. 1. Determination of creatine kinase MB activity with inter-
nal calibration. Bioluminescent assay, time course pf light
emission curve.
y-axis: light intensity (mV), x-axis: tirne (notice: different
time scales).
Pi-Ps: pipetting Steps, indicated by afrows.
PI : CK reagent (900 μ|), anti-M antibodies (20 μΐ), serum
(20 μΐ).
P2: 20 μΐ of ADP (25 mmol/1)
P3: 20 μΐ of ATP (10 μιηοΐ/ΐ)
P4i 20 μΐ of creatine phosphate (0.5 mol/l)i
P5: 20 μΐ of ATP (10 μιηοΐ/ΐ)
SIopCAK and SlopeMB + Ακ: slopes due to the adenylate'ki-
nase and creatine kinase MB activities (····)
IAK and IMB + AK: increase of light emission after internal
calibration with ATP Standards.
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Total c r e a t i n e kinase ac t iv i ty
Wc measured total creatine kinase activity with the 44N-acetylcys-
teine reactivated" kit (No. 14109-141II, E. Merck, Darmstadt,
F.R.G.) (7) using an ACP 5040 Instrument (Eppendorf Ger te-
bau, Hamburg, F.R.G.).
I m m u n o i n h i b i t i o n test
We determined MB isoenzyme activity with "N-acetylcysteine
reactivated" reagents (No. 14109, 14110, 14112, E. Merck,
Darmstadt, F.R.G.) using an ACP 5040 Instrument s described
elsewhere (6).
Rcagent b l a n k s
Reagent blanks were determincd by pipetting the same volume of
NaCl solution (154 mmol/l) instead of serum.
I n f l u e n c e of 2 -mercap toe thano l
We appropriately diluted fresh serum with 154 mmol/l NaCl solu-
tion and determined its creatine kinase activity five times. Subse-
quently another part of this serum was diluted in the same way but
simultaneously we added incrcasing amounts of 2-mercapto-
ethanol (r nge: 0—200 mmol/l). Afterwards the enzyme activities
were analysed twice.
I n a c t i v a t e d se rum
Heating of normal serum at 56 °C for l h dcstroyed all creatine
kinase activity. This serum showed a pH value of 7.45 after heat-
ing.
Results
Reagent b lanks and detect ion l i rn i t s
Table 2 shows our results from the determination of
the reagent blanks. The detection limits for 20 μΐ of
sample volume (>x + 3s) were calculated from the
data of table 2:
total creatine kinase (LKB): l U/l,
creatine kinase MB (LKB): l U/l,
creatine kinase MB (Merck, ACP 5040): 3 U/l.



































and with commercial reference materials. Results
are shown in tables 3 and 4. The precision of the
creatine kinase assay is greatly influenced by the pre-
cision of the ICK and IMB + AK values. The higher the
creatine kinase activity the higher is the imprecision
of the ICK values determined by the databox. There-
fore, imprecision of the assay significantly increased
when creatine kinase activities exceeded 50 U/l. At
low creatine kinase MB activities we found no
marked difference between the results obtained with
the two modifications of the calculation procedure
(using IMB + AK or ΪΜΒ+ΑΚ).
Tab. 3. Within-run precision, determined with individual ICK or
IMB + AK values (databox) and average ICK and ΪΜΒ + ΑΚ
values.
Average I





























s (U/l) Number of runs
1.7 24
1.2 21



































Within-day precision was determined with fresh se-
ra; day-to-day precision was determined with sera
which were kept frozen until the day of the assay,
Scronorm CK-MB (E. Merck, Darmstadt) lot: 513
(Na*: 132 mmol/l, K+: 1.4 mmol/l, phosphate: 0.5 mmol/l, uric
acid: 29.7 μιηοΐ/ΐ, urea: 1.7 mmol/l, creatinc: 35 μπιοΙ/Κ Ca2+:
1.9 nimol/1, lactate: 4.0 mmol/l)
Monitrol I (AHS Deutschland, M nchen)
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Accuracy of the bioluminescent assay may be influ-
enced by serum constituents. This was the case with
Seronorm, where it was impossible to reproduce the
assigned value for total creatine kinase activity with
the bioluminescent assay. The nature of the interfer-
ing substance(s) is unknown and the observed influ-
ence was not due to urea and creatinine or the elec-
trolytes of this reference material (tab. 4).
L i n e a r i t y
We checked linearity by pipetting various sample vo-
lumes into the reaction mixture. In contrast to the
spectrophotometric assay, in the bioluminescent as-
say the rate of increase of light emission is independ-
ent of the final test volume. Therefore doubling the
sample volume doubles the resulting enzyme activi-
ty. Creatine kinase activity was linearily related to
the sample volumes in a ränge of at least 5 to 80
(N = 6; y = 0.17 + 0.67 x; r = 0.999; sy.x = 0.26)
and to at least 0-450 U/l (results not shown).
I n f l u e n c e öf 2 - m e r c a p t o e t h a n o l and of
sample d i l u t i o n
2-Mercaptoethanol: We evaluated possible interfer-
ence in the luciferase indicator reaction by the wide-
ly used thiol-reagent, 2-mercaptoethanol. Table 5
shows that 2-mercaptoethanol does not affect the to-
tal creatine kinase activity.
Tab. 5. Influence of 2-mercaptoethanol on the bioluminescent
assay.
2-Mercaptoethanol 0 4 10 30 50 100 150 200
(mmol/l)
Creatine kinase 75.7 75.1 77.1 76.2 75.1 74.1 71.3 74.1
(U/l)
Sample dilution: Dilution of the sample with bovine
serum albumin solution (Enzyme Diluent, DuPont,
Wilmington, USA), heat inactivated serum or sodi-
um Chloride solution and its influence on the result-
ing creatine kinase activities is shown in table 6.
Tab. 6. Influence of sample dilulion on total creatine kinase ac-
tivity (bioluminescent assay, average of fivefold determi-
nations).
Dilution Diluent
Serum -t- bovine serum
diluent albumin
heat inactivated sodium Chloride

























Compar i son of m c t h o d s
Figures 2 and 3 demonstrate the correlation of the
results obtained with the bioluminescent assay for
creatine kinase MB with those of the spectrophoto-
metric assay. In every case we plotted the mean of
two results obtained with the biojuminescent method
50-
10 x' 20 30 40 50
Creatine kinase MB (spectrophotometric assay) [U/l]
Fig. 2. Correlation between the bioluminescent (y-axis) and the
spectrophotometric (x-axis) assays of creatine kinase MB
activity. Range: 2-50 U/l. N = 76.
Standardized principle component: y = 0.07 + l.OOx; r =
0.98; Sy.v = 1.54: x = 11.2, y = 11.3; there is no signifi-
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Creatine kinase M B (spectrophotometric assay) [U/ l ]
Fig. 3. Comparison of sera with creatine kinase MB activities
<15 U/l. Y-axis: bioluminescent, x-axis spectrophotomet-
ric assay. N = 60.
Standardized principle component: y = 0/72 + 0.92x; r =
0.82; sy = 1.27; x = 6.5, y = 6,6; there exist no signifi-
cant differences between x and y, and between fhe slope b
and l .00 (t-test, 2 P = 0.99).
x: fresh sera; O: sera storcd trozcn until the day of the as-
say.
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s a function of only one result obtained with the
mechanized spectrophotometric assay. Regression
analysis (Standard principle component (8)) shows
that both methods are in good agreement, even at
Iow creatine kinase MB activities. We found no sig-
nificant differences between fresh and deep-frozen
sera.
Cornparison of total creatine kinase activities by bio-
luminescent and spectrophotometric assays resulted
in almost identical values for both methods. Regres-
sion analysis (Standard principle component) for sera
with enzyme activities between 12 and 450 U/l
yielded the following results: N = 42, χ = 114.4, y =
116.8, y = -1.41 + 1.033 x, r = 0.99, sy.x = 8.32.
There was no significant difference between χ and y
and between the slope b and 1.00 (t-test, 2 P =
0.99).
Discussion
Determination of the MB isoenzyme of creatine ki-
nase by immunoinhibition in sera of patients sus-
pected of having myocardial infarction is commonly
accepted. Recently a modification of the spectropho-
tometric method (3) using firefly-bioluminescence
for the indicator reaction was introduced (2). This is
claimed to be more sensitive than the spectrophoto-
metric assay, and therefore capable of wider clinical
application.
Our purpose was to evajuate the analytical perfor-
mance of the new kit, and further, to compare its
results with those obtained with the spectrophoto-
metric assay. In order to investigate specific proper-
ties of the luciferase System, we usually chose only
the easier-to-perform total creatine kinase determi-
nation. At this stage of evaluation we were not inter^
ested in utilizing the high sensitivity of the new sys-
tem for clinical purposes: e.g. earlier diagnosis of
acute myocardial infarction or samples other than
serum.
Two steps in the manual bioluminescent assay of to-
tal creatine kinase and creatine kinase MB aetivities
were found to be critieal: calibration with the inter-
nal ATP Standard, and the tinne at which the slopes
are measured. This was especially true if the databox
was used for calculation of the results. We recom-
mend that the sudden increase of light emission due
to the internal calibration (!CK or IMB+AK) be deter-
mined after exactly 10 seconds. Otherwise the lag
phase of a few seconds (fig. 1) may cause falsely Iow
values for ICK or IMB+AK. Furthermore, our expe-
rience with creatine kinase activities exceeding 50
U/l showed that it is preferabJe to monitor the slopes
due to the creatine kinase reaction for exactly 20 se-
conds (after a lag phase of 10 seconds) instead of
choosing variable measuring times of between 10
and 60 seconds. At shorter intervals creatine kinase
activities may be underestimated. This is due to devi-
ations of the linearity of the light emission. At Iow
enzyme activities we saw no significant differences in
the precisions using either individual ICK and IMB + AK
values or the average Ϊ for calculating the enzyme
activity. In contrast to published results (2) impreci-
sion slightly increased if the individual ICK values
were used, but the differences only became signifi-
cant at higher creatine kinase activities (tab. 3). In
these cases the databox determined the individual
ICK or IMB + AK rather imprecisely; reliable enzyme
activities then could only be achieved with the aver-
age ICK or IMB + AK values. Nevertheless, individual
internal calibration by ATP Standards is useful: some_
sera (tab. 4) may contain unknown compounds
which strongly interfere with the luciferase indicator
reaction, leading to surprisingly Iow ICK values. Only
the individual internal calibration can detect such se-
ra and can give an exact result at least for creatine
kinase activities up to 40 U/l.
The within-run and day-to-day precisions of the
manual bioluminescent assay were high, and at very
Iow creatine kinase MB activities its coefficient of
Variation was significantly better than the coefficient
of Variation of the mechanized spectrophotometric
assay. Highly sensitive creatine kinase MB determi-
nations below the upper reference limit are therefore
possible. The detection limit of the bioluminescent
assay was l U/l, but this result is biased by a reagent
blank of 0.7 U/l, a value we determined in all of our
lots of reagent. If the bias is compensated for by sub-
tracting the constant reagent blank of 0.7 U/I, then
the detection limit is lowered to 0.3 U/l. By increas-
ing the sample volume of the bioluminescent assay
the detection limit may be further decreased to
about 0.06 U/l.
2-Mercaptoethanol showed no influence on the en-
zyme activities, thus permitting analyses of sera
stored with thiol-containing reagents s additives.
Dilution of the samples with bovine serum albumin,
inactivated human serum or sodium Chloride solu-
tion generally resulted in increasing rates of recovery
of the creatine kinase activity. On the other hand,
the linearity of the bioluminescent assay yielded ex-
cellent values up to a volume fraction of serum of at
least 0.08. Therefore the increase of recovery in the
dilution experiment is apparently caused by reactiva-
tion of the creatine kinase during storage after dilu-
tion. The linear relation between sample volume and
enzyme activity shows that the bioluminescent assay
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is well suited to measure creatine kinase MB activi^
ties in a ränge of below l U/l to at least 450 U/l and
therefore fulfills the requirements needed for the di-
agnosis of myocardial infarction (9).
Although the concentrations of the Substrates ADP
and phosphocreatine äs well äs the concentrations of
the adenylate kinase inhibitors are very different in
the bioluminescent and spectrophotometric assays,
we did not find any discrepancies in the measured
enzyme activities for total creatine kinase of for the
MB isoenzyme. Even at low creatine kinase MB ac-
tivities both assays correspond very well, but at crea-
tine kinase MB activities below 10 U/l imprecision
of the spectrophotometric assay increases rapidly
making comparisons difficult.
In the manual procedure the high sensitivity and pre-
cision of the bioluminescent assay for creatine kinase
MB necessitates several pipetting Steps and a striet
time schedule. A meehanized System shotild circum-
vent these drawbacks and make the bioluminescent
assay suited for routine of stat an^lysesin the labora-
tory. Diagnostie improvements with respect to earli-
er confirmation or denial of acute myocardial infarc-
tion, which may arise from this highly sensitive assay,
have still to be investigated.
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